Peptides are short chains of amino acids, usually between two and fifty residues, joined by amide (peptide) bonds. In biology they act as hormones, neurotransmitters, growth factors, antimicrobial agents and enzyme inhibitors, mostly by binding specific receptors on cell surfaces. So what are peptides and what do they do in the laboratory? Researchers use synthetic peptides to probe receptor signalling, measure enzyme activity, model protein folding, raise antibodies and calibrate mass spectrometers. This article explains their structure, how they signal, landmark published studies, laboratory applications, and the purity, storage and handling requirements that determine whether peptide experiments can be reproduced.
What are peptides and what do they do in biology?
A peptide is a linear or cyclic polymer of amino acids. Each amino acid contributes an amino group, a carboxyl group and a distinctive side chain, and the carboxyl group of one residue condenses with the amino group of the next to form a peptide bond. This bond is planar and has partial double-bond character, which restricts rotation and gives peptide chains their characteristic geometry. The order of residues, written from the free amino end (the N-terminus) to the free carboxyl end (the C-terminus), is the primary sequence, and it determines charge, hydrophobicity, folding tendency and receptor affinity.
Naming follows size. Two residues make a dipeptide, three a tripeptide, and chains of up to about ten or twenty are often called oligopeptides. Chains of up to roughly fifty residues are generally called peptides, and longer chains are termed polypeptides or proteins, although the boundary is a convention. The average amino acid residue contributes about 110 daltons, so a ten-residue peptide weighs a little over one kilodalton, while a 29-residue peptide weighs about three. Insulin, with 51 residues in two chains, sits near 5.8 kilodaltons and illustrates the overlap between peptide and protein.
The history of the field explains much of its terminology. Emil Fischer proposed the peptide-bond concept and coined the word “peptide” in 1902. In the same year, Bayliss and Starling described secretin, a 27-residue gut peptide, in the experiments that introduced the idea of chemical messengers carried in the blood. Frederick Sanger determined the complete sequence of insulin in the early 1950s, showing that a protein has a defined primary structure. Vincent du Vigneaud synthesised oxytocin in 1953, the first peptide hormone made in the laboratory, and Bruce Merrifield introduced solid-phase peptide synthesis in 1963, the method that underpins nearly all modern production.
Biologically, peptides do three broad things. They carry signals between cells, as hormones and neuromodulators. They defend tissues, as antimicrobial peptides that disrupt microbial membranes. And they regulate enzymes, as natural inhibitors and as fragments released when larger proteins are cleaved. Many of the peptides that researchers buy are synthetic versions of these natural molecules, or designed analogues of them.
Mechanism of action
Most signalling peptides act by binding receptors on the cell surface, and the largest group of receptors involved is the G protein-coupled receptor (GPCR) family. A GPCR is a seven-transmembrane protein. When a peptide ligand binds its extracellular face, the receptor changes conformation and activates a heterotrimeric G protein on the inner face of the membrane. Depending on the receptor, the response can be an increase in cyclic AMP through Gs, a rise in intracellular calcium through the phospholipase C pathway and Gq, or an inhibition of cyclic AMP through Gi. These second messengers then act on kinases, ion channels and transcription factors to change cell behaviour.
Other peptides use different routes. Insulin-like growth factors bind receptor tyrosine kinases, which phosphorylate themselves and recruit adaptor proteins to start cascades such as the PI3K and Akt pathway. Some peptides act on ion channels directly, as many venom toxins do, blocking or modifying channel gating. Antimicrobial peptides often need no classical receptor at all, since their cationic and amphipathic structure lets them interact with negatively charged microbial membranes. Peptide inhibitors bind enzyme active sites or the interfaces between proteins.
Signalling is also limited in time. Most peptides are degraded by proteases within minutes in biological fluids, and receptors are desensitised by phosphorylation and by arrestin-mediated internalisation, which is why the duration of a response depends as much on clearance as on binding. Researchers address this in the laboratory by using analogues with D-amino acids, cyclisation or terminal capping, which resist proteolysis. This also explains why sequence fidelity matters: a single substituted residue can change receptor affinity by orders of magnitude, so mechanistic conclusions are only as reliable as the identity of the material tested.
What the research shows
Four areas of published work show how peptide research has developed. Readers should consult the primary papers for methods and data.
The first is the discovery of ghrelin by Kojima and colleagues, published in Nature in 1999. The group worked from a known orphan receptor, the growth hormone secretagogue receptor, and searched for its natural ligand. They purified an endogenous ligand from rat stomach, a peptide of 28 amino acids in which serine 3 carries an n-octanoyl group. The modified peptide released growth hormone both in vivo and in vitro, and the octanoyl group at serine 3 was essential for that activity. The study is a model of the “reverse pharmacology” approach, and it is available on PubMed.
The second is the 1988 study by Maquart and colleagues in FEBS Letters, which examined the copper-binding tripeptide glycyl-L-histidyl-L-lysine in cultured fibroblasts. The effect on collagen synthesis began between 10⁻¹² and 10⁻¹¹ M, peaked at 10⁻⁹ M and was independent of any change in cell number. The authors noted that the tripeptide sequence occurs within type I collagen and proposed that it might be released by proteases at a site of tissue injury. The paper is a useful example of how a very short peptide can be characterised in a simple cell-culture system, and the record is on PubMed.
The third is du Vigneaud’s synthesis of oxytocin in the early 1950s. The study showed that a nine-residue peptide, assembled chemically and closed into a ring by a disulfide bridge, reproduced the activity of the natural hormone in classical bioassays. Its significance is methodological: it established that biological activity could be recreated from a defined chemical structure, and it was recognised with the Nobel Prize in Chemistry. Readers wanting the experimental details should consult the original publications and later reviews.
The fourth is Merrifield’s development of solid-phase synthesis, reported in 1963. By anchoring the growing chain to an insoluble polymer, the method allowed excess reagents and by-products to be removed by washing, replacing laborious purification after each coupling. Later refinements, including Fmoc chemistry and automated synthesisers, made long, high-purity peptides practical to produce, and this advance is the reason synthetic peptides are available to research laboratories today.
Research applications
The laboratory uses of peptides follow from the biological functions described above, and the choice of compound follows the experimental question.
In receptor pharmacology, synthetic peptides serve as agonists, antagonists and competitors in binding assays on transfected cell lines, allowing researchers to measure affinity, potency and signalling bias. In cell biology, they are applied to cultured fibroblasts, keratinocytes, myoblasts, neurons and immune cells to study differentiation, migration, matrix synthesis and cytokine release, with readouts such as ELISA, quantitative PCR and phospho-specific immunoblotting.
In enzymology, short peptide substrates, often carrying fluorogenic or chromogenic tags, are used to measure protease and kinase activity, and peptide inhibitors help define active-site requirements. In immunology, defined peptide epitopes stimulate T cells in vitro and are used to characterise antigen presentation and to raise antibodies. In structural biology and biophysics, peptides serve as models for helix formation, aggregation and folding, and isotopically labelled versions are used in NMR and mass-spectrometry studies.
In analytical chemistry, peptides are calibration standards and reference materials for liquid chromatography and mass spectrometry, including method development for peptide mapping and proteomics. In formulation science, they are model compounds for studying stability, aggregation and the behaviour of lyophilised powders. Across all of these settings, the reliability of the data depends on the identity and purity of the starting material.
Purity, storage and handling
Purity verification begins with reversed-phase high-performance liquid chromatography (RP-HPLC), usually with UV detection at 214 or 220 nm. This separates the target peptide from deletion sequences, truncated chains and incompletely deprotected by-products, and it reports purity as the percentage of total peak area belonging to the target. For most cell-based and receptor assays, a purity of 98% or higher is commonly specified, although the acceptable threshold depends on the sensitivity of the experiment. HPLC alone does not prove identity, so it should be paired with mass spectrometry confirming that the observed mass matches the theoretical value for the intended sequence.
A batch-specific certificate of analysis matters because synthesis is never perfectly repeatable. Two lots of the same sequence can differ in purity, counter-ion content, water content and net peptide content, and a generic specification sheet cannot capture that variation. A proper certificate lists the lot number, chromatogram, mass-spectrometry result and analysis date, so that a result can be traced to a specific vial. Because degradation accelerates once a peptide is reconstituted, batch-level verification matters more than many researchers expect. UK laboratories asking what are peptides and what do they do before choosing a source should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and the practical checks for comparing suppliers are set out in How to buy best peptides.
Lyophilised peptides are most stable when kept dry, sealed and cold. Storage at -20°C is the usual recommendation for the long term, and -80°C is sometimes preferred for sensitive sequences. Vials should be brought to room temperature in a desiccator before opening, because condensation introduces moisture that promotes hydrolysis. Sequences rich in cysteine, methionine or tryptophan are prone to oxidation and benefit from storage under inert gas, while those containing asparagine or glutamine can undergo deamidation over time.
Reconstituted peptides are far less stable than the dry powder. Once dissolved, they are exposed to hydrolysis, oxidation, aggregation and microbial contamination, so stock solutions are normally prepared in sterile water or a suitable buffer, divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Hydrophobic sequences may need a small proportion of an organic solvent such as DMSO, matched against the tolerance of the assay. Stability in solution is sequence-specific, and researchers should consult supplier data and validate it under their own conditions.
Light sensitivity is a further consideration. Peptides containing tryptophan or tyrosine, and those carrying fluorophore labels, can undergo photo-oxidation, so vials are best stored in the dark or in amber glass and bench exposure kept short. Each aliquot should be labelled with the date, lot number and concentration so that any later anomaly can be traced.
Frequently asked questions
What is the difference between a peptide and a protein?
The distinction is mainly one of size. Chains of up to roughly fifty amino acids are usually called peptides, and longer chains are termed proteins, although the boundary is conventional rather than absolute. Peptides often lack the stable folded structure of proteins, and they are typically made by chemical synthesis rather than expressed in cells.
How are synthetic peptides made?
Most research peptides are made by solid-phase peptide synthesis, in which the chain is assembled residue by residue on an insoluble resin using protected amino acids. The finished peptide is cleaved from the resin, purified by preparative HPLC and freeze-dried. Merrifield introduced the method in 1963, and Fmoc chemistry is now the most common variant.
How should lyophilised peptides be stored?
Keep lyophilised peptides sealed, dry and protected from light, usually at -20°C for long-term storage. Allow the vial to reach room temperature in a desiccator before opening, so that condensation does not introduce moisture. Sensitive sequences containing methionine or cysteine may benefit from storage under inert gas or at -80°C.
How do I check the purity of a research peptide?
Ask for the batch-specific certificate of analysis and check that it shows an RP-HPLC chromatogram with percentage purity and a mass-spectrometry result matching the theoretical molecular weight. Together these confirm both purity and identity. For critical experiments, independent analysis by your own facility or a third-party laboratory provides further assurance.
The compounds discussed in this article are supplied for in-vitro laboratory research only and are not for human or veterinary use.